Methadone maintenance treatment (MMT) involves the daily administration of
the oral opioid agonist methadone as a treatment for opioid dependence-a pe
rsistent disorder with a substantial risk of premature death. MMT improves
health and reduces illicit heroin use, infectious-disease transmission, and
overdose death. However, its effectiveness is compromised if low maintenan
ce doses of methadone (<60 mg) are used and patients are pressured to becom
e prematurely abstinent from methadone. Pregnancy and psychiatric comorbidi
ty are not contraindications for MMT. As an alternative to MMT, other oral
opioid agents (eg, naltrexone, buprenorphine) may increase patient choice a
nd avoid some of the more unpleasant aspects of MMT. The public-health chal
lenge for the future is to develop and continue to deliver safe and effecti
ve forms of opioid maintenance treatment to as many opioid-dependent indivi
duals as can benefit from them.